OncoPharm podcast

Prostate Cancer Screening, DasaHit, & CHARGE Index

11/19/2026
0:00
15:30
Rewind 15 seconds
Fast Forward 15 seconds
The American Cancer Society rolls out updated screening recommendations for prostate cancer, that includes every 2 year PSA beginning at age 50 for standard risk and 45 for high risk (e.g. Black patients). A randomized trial suggests an alternate dasatinib dosing (100 mg daily on weekdays) is non-inferior with regards to MMR at 2 years compared to 100 mg daily dosing. Finally, the CHARGE index appears prognostic for PFS in multiple myeloma treated with Bispecific T-cell therapies. Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

More episodes from "OncoPharm"